Arrowhead climbs on licensing agreement with Novartis for upto $2 billion

Arrowhead Pharmaceuticals

02/09/2025 14:08

** Shares of Arrowhead Pharmaceuticals ARWR.O rise 5% to $23.20 premarket

** Co says it will receive up to $2 billion from Novartis NOVN.S for an exclusive worldwide license to its experimental therapy ARO-SNCA that targets neuromuscular conditions such as Parkinson's Disease

** Arrowhead will receive $200 million and up to $2 billion in milestone payments and royalties on future sales of the therapy

** Up to last close, stock was up 17.2% YTD

(Reporting by Christy Santhosh)

((Christy.Santhosh@thomsonreuters.com))